Cargando…

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

BACKGROUND: The association of early changes in the immune infiltrate during neoadjuvant chemotherapy (NACT) with pathological complete response (pCR) in triple-negative breast cancer (TNBC) remains unexplored. METHODS: Multiplexed immunohistochemistry was performed in matched tumor biopsies obtaine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graeser, Monika, Feuerhake, Friedrich, Gluz, Oleg, Volk, Valery, Hauptmann, Michael, Jozwiak, Katarzyna, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kolberg-Liedtke, Cornelia, Kates, Ronald, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans Heinrich, Harbeck, Nadia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108653/ https://www.ncbi.nlm.nih.gov/pubmed/33963012 http://dx.doi.org/10.1136/jitc-2020-002198

Ejemplares similares

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2022)

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
por: Nitz, Ulrike, et al.
Publicado: (2020)

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2(+)/HR(−) Trial
por: Graeser, Monika, et al.
Publicado: (2023)

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2020)

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
por: Harbeck, Nadia, et al.
Publicado: (2021)

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2017)

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2019)

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer
por: Grote, Isabel, et al.
Publicado: (2022)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
por: Wuerstlein, R., et al.
Publicado: (2019)

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
por: Hofmann, Daniel, et al.
Publicado: (2013)

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
por: de Gregorio, Amelie, et al.
Publicado: (2022)

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic
por: Dowsett, Mitch, et al.
Publicado: (2020)

Clinical validity and clinical utility of Ki67 in early breast cancer
por: Kreipe, Hans, et al.
Publicado: (2022)

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
por: Degenhardt, Tom, et al.
Publicado: (2023)

High-dose chemotherapy with peripheral blood progenitor cell support in breast cancer: WSG AM01 and MM01
por: Nitz, U, et al.
Publicado: (2001)

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
por: Bruzas, Simona, et al.
Publicado: (2022)

Is Upregulation of BCL2 a Determinant of Tumor Development Driven by Inactivation of CDH1/E-Cadherin?
por: Karch, Inga, et al.
Publicado: (2013)

Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis
por: Christgen, Matthias, et al.
Publicado: (2016)

Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
por: Christgen, Matthias, et al.
Publicado: (2021)

Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology
por: Hasemeier, Britta, et al.
Publicado: (2008)

WSG, a Glucose-Rich Polysaccharide from Ganoderma lucidum, Combined with Cisplatin Potentiates Inhibition of Lung Cancer In Vitro and In Vivo
por: Qiu, Wei-Lun, et al.
Publicado: (2021)

Challenges in Antibody Development against Tn and Sialyl-Tn Antigens
por: Loureiro, Liliana R., et al.
Publicado: (2015)

Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma
por: Sflomos, George, et al.
Publicado: (2023)

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
por: Gluz, Oleg, et al.
Publicado: (2020)

Insertion site preference of Mu, Tn5, and Tn7 transposons
por: Green, Brian, et al.
Publicado: (2012)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Detection of Tn7-Like Transposons and Antibiotic Resistance in Enterobacterales From Animals Used for Food Production With Identification of Three Novel Transposons Tn6813, Tn6814, and Tn6765
por: He, Juan, et al.
Publicado: (2020)

High frequency of lobular breast cancer in distant metastases to the orbit
por: Raap, Mieke, et al.
Publicado: (2015)

Trust based attachment
por: Kates-Harbeck, Julian, et al.
Publicado: (2023)

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
por: Arboleda, Bolivar, et al.
Publicado: (2022)

Recover your smile: Effects of a beauty care intervention on depressive symptoms, quality of life, and self‐esteem in patients with early breast cancer
por: Richard, Anna, et al.
Publicado: (2018)

Investigation of the prevalence of Tn916/Tn916-like elements in oral streptococci
por: Lunde, Tracy
Publicado: (2017)

Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG
por: Matsumoto, Yasuyuki, et al.
Publicado: (2023)

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

Prevalence, diversity and transferability of the Tn916-Tn1545 family ICE in oral streptococci
por: Lunde, Tracy Munthali, et al.
Publicado: (2021)

HUIL-TN & HUI-TN: Mining high utility itemsets based on pattern-growth
por: Wang, Le, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4iuudng0nqp3f7eq969ajcsoao